IMW 2019 | A.R.R.O.W. study: carfilzomib dosing in frail MM patients
Maria-Victoria Mateos, MD, PhD from the University of Salamanca, Salamanca, Spain, gives an update on the Phase III A.R.R.O.W. study (NCT02412878) looking at carfilzomib dosing in frail MM patients. Dr Mateos was speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
